Stockscreener 앱 받기
54.73
3.13%
1.66
Cg Oncology Inc 주식(CGON)의 최신 뉴스
Investment Review: Can CG Oncology Inc sustain earnings growthEarnings Performance Report & High Win Rate Trade Tips - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Revenue Check: Is CG Oncology Inc stock a hidden gemRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Gainers Report: Is Citigroup Capital XVI Preferred Security stock undervalued right nowEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
CGON: Pivotal data and regulatory milestones position a novel NMIBC therapy for major market expansion - TradingView — Track All Markets
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
CG Oncology Expands At-The-Market Equity Offering Capacity - The Globe and Mail
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI
Why CG Oncology Stock Is Suddenly Climbing Higher - TipRanks
Travel Stocks: What is the target price for CG Oncology Inc stock2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Aug Highlights: Will CG Oncology Inc outperform the market in YEARPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com India
Mulay, James sells CG Oncology (CGON) shares for $584,798 - Investing.com
CG Oncology files amendment to increase stock offering to $550 million By Investing.com - Investing.com Nigeria
James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat
CG Oncology files amendment to increase stock offering to $550 million - Investing.com
CG Oncology Files Amendment to Increase Stock Offering - TradingView — Track All Markets
Aug Spikes: Is Skeena Resources Limited attractive for institutional investorsDollar Strength & Weekly Top Stock Performers List - baoquankhu1.vn
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - MSN
Institution Moves: Why analysts upgrade CG Oncology Inc. stockJuly 2025 Fed Impact & AI Enhanced Trading Signals - Bộ Nội Vụ
Truist Securities raises CG Oncology stock price target to $66 on early trial data - Investing.com Canada
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
CG Oncology Expedites PIVOT-006 Phase 3 Topline Data Readout In Intermediate-Risk NMIBC To H1 2026 - Nasdaq
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week - TechStock²
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next - TechStock²
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next - TechStock²
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Sahm
CG Oncology accelerates timeline for bladder cancer trial data By Investing.com - Investing.com Nigeria
Cg Oncology stock hits 52-week high at 46.19 USD By Investing.com - Investing.com Nigeria
Is CG Oncology Inc. stock supported by strong cash flowsJuly 2025 Setups & High Accuracy Swing Trade Signals - Улправда
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 TimelineHas The Bull Case Changed? - Yahoo Finance
Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance
CG Oncology’s Bladder Cancer Bet Heads Toward A Big 2026 Test - Finimize
Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating - TipRanks
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade
CG Oncology Price Target Raised Amid Robust Market Prospects - timothysykes.com
CG Oncology stock price target raised to $93 from $89 at Morgan Stanley - Investing.com Canada
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology - TipRanks
CG Oncology rises after expediting a late-stage trial readout for lead asset - Seeking Alpha
Midday Stock Roundup: loanDepot Rises on Trump Move - Orange County Business Journal
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026 - TechStock²
CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target - TipRanks
CG Oncology to Share Data From Phase 3 Bladder Cancer Trial a Year Ahead of Schedule; Shares Up - marketscreener.com
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighTime to Buy? - MarketBeat
CG Oncology Stock Boosted by Price Target Increase - timothysykes.com
Is Accelerated PIVOT-006 Data for Cretostimogene Reshaping the Investment Case for CG Oncology (CGON)? - Sahm
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
CG Oncology stock soars after Phase 3 trial data timeline accelerated - Investing.com Nigeria
CG Oncology stock soars after Phase 3 trial data timeline accelerated By Investing.com - Investing.com South Africa
Why CG Oncology Stock Is Sliding Despite Trial Boost - TipRanks
CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline - TipRanks
Cg Oncology provides updated timeline for Pivot-006 phase 3 topline data in intermediate-risk NMIBC - marketscreener.com
4.73%
0.92%
자본화:
|
볼륨(24시간):